A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)

Key facts

Sponsor

Takeda

Principal Investigator

Study Director

Takeda

Intervention

Maralixibat(drug)

Enrollment

50 enrolled

Eligibility

All sexes

Timeline

2026 – 2031

Study locations (1)

• Takeda selected site, Tokyo, Tokyo, Japan

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Alagille syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07411716
  Pediatric Evaluation and Registry for Liver Cholestasis in Canada
  Children's Hospital of Eastern Ontario
• RECRUITINGPHASE4NCT07290257
  Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU)
  Mirum Pharmaceuticals, Inc.
• RECRUITINGNCT06850038
  A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
  Ipsen
• RECRUITINGNCT06193928
  Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)
  Mirum Pharmaceuticals, Inc.
• RECRUITINGPHASE3NCT05035030
  Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
  Albireo, an Ipsen Company

See all trials for Alagille syndrome →